Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Investment Implications of the Acquisition of MAP Pharmaceuticals by Allergan

Allergan to Acquire MAP Pharmaceuticals
Allergan (AGN) has announced that it will acquire MAP Pharmaceuticals (MAPP) at a price of $25…
Read more…

Levadex Receives Complete Response Letter, What Does This Mean for the Stock? (MAPP, $16.44)

Summary
I think that it is a question of when and not if Levadex is approved. The complete response letter or…
Read more…

Levadex Has a Good Chance for Approval on its March 26th PDUFA Date (MAPP, $17.09)

Investment Opinion, In Brief
The PDUFA date for Levadex, MAP Pharmaceutical's lead product, is looming on March 26, 2012. I believe…
Read more…

Initiating Coverage of MAP Pharmaceuticals with A Buy Based On Potential for Levadex (MAPP, $13.35)

Investment Opinion
Map Pharmaceuticals is poised to introduce its first commercial product, Levadex (inhaled dihydroergotamine) that is indicated for treating acute…
Read more…